Tony Coles has degrees from Johns Hopkins, Harvard, and Duke. He’s a cardiologist by training and practiced medicine at Massachusetts General Hospital. He’s a Big Pharma veteran, having spent time in executive positions at Merck and Bristol-Myers Squibb.

But Coles is probably best known for his work in the biotech world. He led NPS Pharmaceuticals for a time, and then in early 2008, he was named CEO of Onyx Pharmaceuticals. It’s in this role that Coles really left his mark. He took over as CEO of the cancer drug maker when it was on some shaky ground with investors and its partner, the German pharma giant Bayer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Arbro is a leading multidisciplinary contract research organization and testing lab in India. Established in the year 1990 having over two decades of experience in pharmaceutical testing, food testing, herbal testing, water testing and construction material.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy